Literature DB >> 33495168

Weeping wounds and sepsis: a complication of elephantiasis nostras verrucosa.

Kenny Vongbunyong1, Chayan Chakraborti2.   

Abstract

Entities:  

Keywords:  heart failure; infections; medical management; skin

Mesh:

Year:  2021        PMID: 33495168      PMCID: PMC7839909          DOI: 10.1136/bcr-2020-239959

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


× No keyword cloud information.

Description

A 68-year-old man with atrial fibrillation, morbid obesity, heart failure and venous stasis dermatitis presented to the emergency department after a presyncopal episode. On arrival he was febrile, hypotensive, tachycardic and found to have leucocytosis, which led to concerns for septic shock. Blood cultures grew group C Streptococcus, prompting treatment with intravenous ceftriaxone. Physical examnation showed extensive bilateral leg swelling with extreme hyperpigmented skin accompanied by multiple keratotic papules and plaques draining white malodorous discharge (figure 1). The patient reported the discharge started 6 months prior, while the nodules developed over the course of 2 years and extended from the malleolus to a few centimetres below the knee. These findings were suggestive of the diagnosis of elephantiasis nostras verrucosa (ENV) superimposed on chronic venous stasis dermatitis. The patient received aggressive diuresis to address the heart failure exacerbation, which led to reduced swelling of his bilateral lower extremities and flattening of the papules and plaques (figure 2).
Figure 1

Characteristic ‘tree-bark’ appearance of ENV showing multiple keratotic papules and plaques. ENV, elephantiasis nostras verrucosa.

Figure 2

Lower right extremity after diuresis.

Characteristic ‘tree-bark’ appearance of ENV showing multiple keratotic papules and plaques. ENV, elephantiasis nostras verrucosa. Lower right extremity after diuresis. ENV is a rare complication of non-filarial chronic secondary lymphoedema that can be caused by conditions impairing lymphatic drainage including recurring erysipelas and cellulitis, congestive heart failure, obesity and chronic venous stasis. Additionally, ENV can be caused by malignancies such as lymphoma, which can impede lymphatic drainage, and soft-tissue trauma which can introduce bacteria to cause infections.1 In particular, obesity and congestive heart failure are two causes of secondary lymphoedema which have increasing prevalence in the USA and can be expected to accompany ENV more frequently in the future.2 ENV is a progressive condition that can lead to irreversible disfiguring skin changes and interfere with ambulation. This case reports sepsis as a consequence of streptococcus skin infection in a patient with ENV, further highlighting the importance of early identification and intervention. ‘I was not bothered by my legs since I was worried about the bigger things like my heart hurting and the A. fib which was occurring all the time. My legs were painless but it started getting worse and worse as the year went on. Then fluid started leaking out like a faucet and whenever I would sit, there would be a puddle. It must have been the infection trying to get out. I am glad that everything is getting taken care of. My legs today are so much better you would think they were a new set of legs.’ Elephantiasis nostras verrucosa (ENV) is a rare non-filarial form of lymphoedema seen in patients with chronic secondary lymphoedema. It is important to recognise and treat ENV early, as the condition can cause irreversible skin changes, interfere with ambulation and increase a patient’s risk for infections.
  2 in total

1.  Elephantiasis Nostras Verrucosa (ENV): a complication of congestive heart failure and obesity.

Authors:  Drew Baird; David Bode; Troy Akers; Zachariah Deyoung
Journal:  J Am Board Fam Med       Date:  2010 May-Jun       Impact factor: 2.657

Review 2.  Elephantiasis nostras verrucosa: a review.

Authors:  Krisanne Sisto; Amor Khachemoune
Journal:  Am J Clin Dermatol       Date:  2008       Impact factor: 7.403

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.